Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT0991 in Relapsed/Refractory Acute Myeloid Leukemia
NCT06709131Phase 1Suspended
- Start
- Jan 2025
- Primary completion
- Aug 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CT0991 in acute myeloid leukemia (AML). Primary endpoint: Adverse Events at 12 months. Started Jan 2025; status: suspended.
02
Drugs
CT0991
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06709131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06709131.